Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)

NCT03349801 is registered in ClinicalTrials.gov with Frank G. Holz as lead sponsor.

NCT NCT03349801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03349801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)
Lead sponsor
Frank G. Holz
Phase
Observational
Overall status
Active, not recruiting
Start date
March 26, 2018
Completion date
February 28, 2026
Enrollment
718 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration (amd)